Sobi publishes report for the third quarter 2020
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2020. Total revenue for the second quarter 2020 was SEK 2,970 M and EBITA was SEK 933 M. July-September · Total revenue of SEK 2,970 M (2,930), up 1 per cent (6 per cent at constant exchange rates (CER)) · EBITA[1] was SEK 933 M (1,099), with an EBITA margin[1] of 31 per cent (38) · Earnings per share before dilution (EPS) of SEK 0.94 (1.84) · Net debt[1] of SEK 12,703 M at 30 September 2020 (15,404 at 31 Dec 2019) · Sales for Elocta® were SEK 1,115 M (